Cover Image

Optimizing Doses of Ceftolozane/Tazobactam as Monotherapy or in Combination with Amikacin to Treat Carbapenem-Resistant <i>Pseudomonas aeruginosa</i>

Carbapenem-resistant <i>Pseudomonas aeruginosa</i> (CRPA) is a hospital-acquired pathogen with a high mortality rate and limited treatment options. We investigated the activity of ceftolozane/tazobactam (C/T) and its synergistic effects with amikacin to extend the range of optimal therap...

Full description

Saved in:

Bibliographic Details
Main Authors:	Worapong Nasomsong (Author), Parnrada Nulsopapon (Author), Dhitiwat Changpradub (Author), Supanun Pungcharoenkijkul (Author), Patomroek Hanyanunt (Author), Tassanawan Chatreewattanakul (Author), Wichai Santimaleeworagun (Author)
Format:	Book
Published:	MDPI AG, 2022-04-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Correction: Nulsopapon et al. The Synergistic Activity and Optimizing Doses of Tigecycline in Combination with Aminoglycosides against Clinical Carbapenem-Resistant <i>Klebsiella pneumoniae</i> Isolates. <i>Antibiotics</i> 2021, <i>10</i>, 736
by: Parnrada Nulsopapon, et al.
Published: (2022)

The Synergistic Activity and Optimizing Doses of Tigecycline in Combination with Aminoglycosides against Clinical Carbapenem-Resistant <em>Klebsiella pneumoniae</em> Isolates
by: Parnrada Nulsopapon, et al.
Published: (2021)

Ceftolozane-Tazobactam Combination Therapy Compared to Ceftolozane-Tazobactam Monotherapy for the Treatment of Severe Infections: A Systematic Review and Meta-Analysis
by: Marco Fiore, et al.
Published: (2021)

Antimicrobials as Single and Combination Therapy for Colistin-Resistant <i>Pseudomonas aeruginosa</i> at a University Hospital in Thailand
by: Supanun Pungcharoenkijkul, et al.
Published: (2020)

Antimicrobial Activity Profiles and Potential Antimicrobial Regimens against Carbapenem-Resistant Enterobacterales Isolated from Multi-Centers in Western Thailand
by: Parnrada Nulsopapon, et al.
Published: (2022)

Does Vancomycin Resistance Increase Mortality? Clinical Outcomes and Predictive Factors for Mortality in Patients with <i>Enterococcus faecium</i> Infections
by: Jatapat Hemapanpairoa, et al.
Published: (2021)

Effectiveness and resource utilization of hospital-based contact tracing of patients and health care workers with COVID-19 at a tertiary teaching hospital in Thailand
by: Worapong Nasomsong, et al.
Published: (2023)

The Potential Use of Ceftazidime-Avibactam Against Carbapenem Resistant Klebsiella pneumoniae Clinical Isolates Harboring Different Carbapenemase Types in a Thai University Hospital
by: Nasomsong W, et al.
Published: (2021)

Is Early Monitoring Better? Impact of Early Vancomycin Exposure on Treatment Outcomes and Nephrotoxicity in Patients with Methicillin-Resistant <i>Staphylococcus aureus</i> Infections
by: Thanawat Chattaweelarp, et al.
Published: (2020)

Clinical Impact of Vancomycin Treatment in Ampicillin-Susceptible Enterococci Bloodstream Infections
by: Jatapat Hemapanpairoa, et al.
Published: (2022)

Ceftolozane/Tazobactam Dosing Requirements Against Bacteremia
by: Jesus Ruiz, et al.
Published: (2020)

Physicochemical Compatibility of Ceftolozane-Tazobactam with Parenteral Nutrition
by: Jan Thomas De Pourcq, et al.
Published: (2024)

Chemical Stability of Ceftolozane/Tazobactam in Polyvinylchloride Bags and Elastomeric Pumps
by: Joseph Terracciano, PhD, et al.
Published: (2017)

Use of Ceftolozane/Tazobactam in a Case of Septic Shock by Puerperal Sepsis
by: Mario Pezzi, et al.
Published: (2019)

Ceftolozane/tazobactam for the treatment of bacteremia: a systematic literature review (SLR)
by: Z. S. Khankhel, et al.
Published: (2022)

Ceftolozane/tazobactam and ceftazidime/avibactam for the treatment of complicated intra-abdominal infections
by: Goodlet KJ, et al.
Published: (2016)

The Comparative Effectiveness of Ceftolozane/Tazobactam versus Aminoglycoside- or Polymyxin-Based Regimens in Multi-Drug-Resistant <i>Pseudomonas aeruginosa</i> Infections
by: Aisling R. Caffrey, et al.
Published: (2022)

Comparative In Vitro Activity of Ceftolozane/Tazobactam against Clinical Isolates of <i>Pseudomonas aeruginosa</i> and <i>Enterobacterales</i> from Five Latin American Countries
by: Juan Carlos García-Betancur, et al.
Published: (2022)

Profile of ceftolozane/tazobactam and its potential in the treatment of complicated intra-abdominal infections
by: Skalweit MJ
Published: (2015)

Critical evaluation of ceftolozane–tazobactam for complicated urinary tract and intra-abdominal infections
by: Giancola SE, et al.
Published: (2016)

Real-Life Experience of Continuously Infused Ceftolozane/Tazobactam in Patients with Bronchiectasis and Multidrug-Resistant <i>Pseudomonas aeruginosa</i> Infection in the Outpatient Setting
by: Francesco Venuti, et al.
Published: (2023)

In Vitro Activity of Ceftolozane-Tazobactam and Other Antibiotics against <i>Pseudomonas aeruginosa</i> Infection-Isolates from an Academic Medical Center in Thailand
by: Woraphot Tantisiriwat, et al.
Published: (2022)

Comparative Evaluation of Vitek 2 and Etest versus Broth Microdilution for Ceftazidime/Avibactam and Ceftolozane/Tazobactam Susceptibility Testing of <i>Enterobacterales</i> and <i>Pseudomonas aeruginosa</i>
by: Arhodoula Papadomanolaki, et al.
Published: (2022)

Cost-effectiveness of ceftolozane/tazobactam for the treatment of complicated intraabdominal and urinary tract infections in Colombia
by: Fabián Hernández
Published: (2020)

Finding the Dose for Ceftolozane-Tazobactam in Critically Ill Children with and without Acute Kidney Injury
by: Laura Butragueño-Laiseca, et al.
Published: (2020)

Ceftolozane-tazobactam for the treatment of osteomyelitis caused by multidrug-resistant pathogens: a case series
by: Xing Tan, et al.
Published: (2019)

Susceptibility of Meropenem-Resistant and/or Carbapenemase-Producing Clinical Isolates of <i>Enterobacterales</i> (<i>Enterobacteriaceae</i>) and <i>Pseudomonas aeruginosa</i> to Ceftazidime-Avibactam and Ceftolozane-Tazobactam as Assessed by In Vitro Testing Methods
by: Venere Cortazzo, et al.
Published: (2022)

The safety of ceftolozane-tazobactam for the treatment of acute bacterial infections: a systemic review and meta-analysis
by: Li-Ting Wang, et al.
Published: (2021)

In Vitro Activity of Ceftolozane-Tazobactam against <i>Escherichia coli</i>, <i>Klebsiella pneumoniae</i> and <i>Pseudomonas aeruginosa</i> Obtained from Blood Cultures from Sentinel Public Hospitals in South Africa
by: Olga Perovic, et al.
Published: (2023)

Ceftazidime/Avibactam and Ceftolozane/Tazobactam for Multidrug-Resistant Gram Negatives in Patients with Hematological Malignancies: Current Experiences
by: Marianna Criscuolo, et al.
Published: (2020)

Combination Therapy versus Monotherapy in the Treatment of <i>Stenotrophomonas maltophilia</i> Infections: A Systematic Review and Meta-Analysis
by: Abhisit Prawang, et al.
Published: (2022)

In-vitro activity of ceftolozane/tazobactam against recent clinical bacterial isolates from two Saudi Arabian hospitals
by: Nezar M. Bahabri, et al.
Published: (2022)

Ceftolozane/Tazobactam for Treating Children With Exacerbations of Cystic Fibrosis Due to Pseudomonas aeruginosa: A Review of Available Data
by: Silvia Garazzino, et al.
Published: (2020)

A Randomized Controlled Trial of Colistin Combined with Sulbactam: 9 g per Day versus 12 g per Day in the Treatment of Extensively Drug-Resistant <i>Acinetobacter baumannii</i> Pneumonia: An Interim Analysis
by: Chutchawan Ungthammakhun, et al.
Published: (2022)

Activity of Ceftolozane/tazobactam and Imipenem/relebactam against Clinical Enterobacteriaceae Isolates Collected in the Middle East - SMART 2016-2018
by: I Alekseeva, et al.
Published: (2020)

Clinical Outcomes of Ceftazidime-Avibactam versus Ceftolozane-Tazobactam in Managing Pseudomonal Infections in Patients Undergoing Renal Replacement Therapy
by: Wasim S. El Nekidy, et al.
Published: (2024)

Role of the multi-drug efflux systems on the baseline susceptibility to ceftazidime/avibactam and ceftolozane/tazobactam in clinical isolates of non-carbapenemase-producing carbapenem-resistant Pseudomonas aeruginosa
by: María José Contreras-Gómez, et al.
Published: (2022)

Use of Ceftolozane/Tazobactam for the Treatment of Multidrug-Resistant <i>Pseudomonas aeruginosa</i> Pneumonia in a Pediatric Patient with Combined Immunodeficiency (CID): A Case Report from a Tertiary Hospital in Saudi Arabia
by: Ahmed Zikri, et al.
Published: (2019)

Ceftolozane/Tazobactam and Ceftazidime/Avibactam for Multidrug-Resistant Gram-Negative Infections in Immunocompetent Patients: A Single-Center Retrospective Study
by: Rosario Cultrera, et al.
Published: (2020)

Activity of ceftolozane/tazobactam and imipenem/relebactam against clinical P. aeruginosa isolates collected in the Middle East - SMART 2016-2018
by: I Alekseeva, et al.
Published: (2020)